Document Type : Brief Report(s)
Authors
1 Department of Biochemistry, Fars Science and Research Branch, Islamic Azad University, Shiraz, Iran
2 Department of Biochemistry, Shiraz Branch, Islamic Azad University, Shiraz, Iran
3 Department of Pathology, Medical School of Shiraz University, Shiraz University of Medical Sciences
4 Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract
Background: Chromogranin is a marker that can be detected in the tissue of the neuroendocrine tumors (NET) by immunohistochemistry and as a biomarker for the diagnosis and follow-up of NET. In this study, we evaluated the correlation of prognostic characteristics of NETs (Ki67, location, and size) with the chromogranin level.
Method: In this case-control study, we measured the serum level of chromogranin in 50 cases of NETs from different locations of the gastrointestinal tract, liver, and pancreas as well as 30 healthy individuals for one year (2016). The correlation of this level was evaluated with Ki67, size, and location of the tumors (main prognostic predictors of NETs).
Results: The level of chromogranin in the above-mentioned 80 tumoral and healthy cases was 37 to 2585 ng/ml (242.3±439.4). The level of chromogranin in NETs and normal cases was 326.3±525.3 and 51.5±16.7, respectively. This level showed a statistically significant correlation with the Ki67 percentage and the tumor grade (P-value <0.05). There was no correlation between size and chromogranin level, but the highest level was detected in liver NETs. The cut-off level of 61.2 ng/ml correlated with the presence of NET with a sensitivity of 80% and specificity of 70%.
Conclusion: Chromogranin level can be used as a prognostic biomarker that is correlated with the grade of NETs and very high levels of this marker can be indicative of liver involvement. The cut-off level of 61.2 ng/ml can be considered as one of the predictors of the NET in the gastrointestinal, liver, or pancreas.
Keywords
How to cite this article:
Azema M, Geramizadeh B. Serum chromogranin level in gastrointestinal, pancreas, and liver neuroendocrine tumors, a brief report. Middle East J Cancer. 2022;13(1):172-6. doi: 10.30476/mejc.2021.86049.1320.
2.Nölting S, Kuttner A, Lauseker M, Vogeser M, Haug A, Herrmann KA, et al. Chromogranin a as serum marker for gastroenteropancreatic neuroendocrine tumors: a single center experience and literature review. Cancers (Basel). 2012;4(1):141-55. doi: 10.3390/ cancers4010141.
3.Syversen U, Ramstad H, Gamme K, Qvigstad G, Falkmer S, Waldum HL. Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol. 2004;39(10):969-73. doi: 10.1080/0036 5520410003362.
4.Geramizadeh B, Kashkooe A, Malekhosseini SA. Liver metastasis of gastrointestinal neuroendocrine tumors: A single center experience. Hepat Mon. 2016;16(5):e37293. doi: 10.5812/hepatmon.37293.
5.Bellizzi AM. Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you? Hum Pathol. 2020; 96: 8-33. doi: 10.1016/j.humpath.
6.Cimitan M, Buonadonna A, Cannizzaro R, Canzonieri V, Borsatti E, Ruffo R, et al. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types. Annals Oncol. 2003;14(7):1135-41. doi: 10.1093/annonc/mdg279.
7.Paik WH, Park JK, Kin YT, Yoon YB. Clinical usefulness of plasma chromogranin A in pancreatic neuroendocrine neoplasms. J Korean Med. 2013; 28:750-4. doi: 10.3346/jkms.2013.28.5.750.
8.Warner PRP, Curran T, Shafir MK, Schiano TD, Khaitova V, Kim MK. Serum and ascites chromogranin A in patients with metastatic neuroendocrine tumor. Pancreas. 2011; 40(4):622-26. doi: 10.1097/MPA. 0b013e3182156c0b.
9.Compana D, Nori F, Picitelli L, Morselli-Labate AM, Pezzilli R, Corinalderi R, et al. Chromogranin A: Is it a useful marker for neuroendocrine tumors? J Clin Oncol. 2007;25(15):1967-73. doi: 10.1200/JCO.2006. 10.1535.
10.Hijioka M, Ito T, Igarashi H, Fujimori N, Lee L, Nakamura T, et al. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors. Cancer Sci. 2014;105(11): 1464-71. doi: 10.1111/cas.12533.
11.Chou WC, Hung YS, Hsu JT, Chen JS, Lu CH, Hwang TL, et al. Chromogranin A is a reliable biomarker for gastropancreatic neuroendocrine tumors in an Asian population of patients. Neuroendocrinology. 2012;95(4):344-50. doi: 10.1159/000333853.
12.Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian multicenter study. Endocrine-Related Cancer. 2007;14(2):773-82. doi: 10.1677/ERC-07-0001
13.Tomassetti P, MIgliori M, Simoni P, Casadei R, Lanio RD, Corinalden R, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumors. Eur J Gastroenterol Hepatol. 2001;13(1):55-8. doi: 10.1097/00042737-200101000-00010.
14.Søndenaa K, Sen J, Heinle F, Fjetland L, Gudlaugsson E, Syversen U. Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report. World J Surg. 2004;28(9):890-5. doi: 10.1007/s00268-004-7384-6.
15.Stridsberg M, Eriksson B, Oberg K, Jonson E. A comparison between 3 commercial kits for chromogranin A measurements. Endocrinol. 2003;177(2):337-41. doi: 10.1677/joe.0.1770337.
16.Ferrari L, Seregni E, Lucignani G, Bajetta E, Martinetti A, Aliberti G, et al. Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. Int J Biol Markers. 2003;19(4):295-304. doi: 10.5301/jbm.2008.1664.
17.Glinicki P, Jeski W. Chromogranin A-the influence of various factors in vivo and in vitro and existing disorders on its concentration in blood. Pol J Endocrinol. 2010;61(4):384-7.
)